

In the Specification:

Please amend the specification as shown:

Please delete the paragraph on page 41, lines 14-18, and replace it with the following paragraph:

cDNA encoding residues 17-125 of HDM2 were cloned and expressed as follows:
PCR was performed using ATCC item number 384988 containing partial human MDM2 sequence as template and the following primers:
Forward: 5'-CTCTCTCGGATCCCAGATTCCAGCTTCGGAACAAGAG (SEQ ID NO: 5)
Reverse: 5'-TATATATCTCGAGTCAGTTCTCACTCACAGATGTACCTGAG (SEQ ID NO: 6).

Please delete the paragraph on page 41, lines 27-32, and replace it with the following paragraph:

For HDM2 23-114, the primers used were as follows:

5' -CGACGATTGGATCCGAACAAAGACCCTG (SEQ ID NO: 7)

3' -GGCTACTACTCCGAGTCATTCCTGCTGATTGACTAC (SEQ ID NO: 8)

For HDM2 17-111, the primers used were

5' -CTCTCTCGGATCCCAGATTCCAGCTTCGGAACAAGAG (SEQ ID NO: 9)

3' -TTCAGCAGCTCGAGTCAATTGACTACTACCAAGTTC (SEQ ID NO: 10)

Please delete the paragraph on page 43, lines 3-14, and replace it with the following paragraph:

The inhibition of MDM2 binding to p53 was measured using a p53 peptide analog binding to MDM2 residues 17-125. The published crystal structure of this complex (Kussie, P.H., *et al.*, *Science* 274:948-953 (1996)) validates this fragment as containing the p53 binding site, and we have solved the X-ray structure of the p53 peptide analog MPRFMDYWEGLN (SEQ ID NO: 11), described to be a peptide inhibitor of the MDM2 p53 interaction (Böttger, A., *et al.*, *J Mol Biol* 269:744-756 (1997)). The assay uses N terminal fluorescein RFMDYWEGL peptide (SEQ ID NO: 12), (F1 9mer). Compound was incubated for 15 minutes with 30 nM fluorescein peptide F1 9mer and 120 nM HDM2 17-125 in 50 mM HEPES pH. 7.5, 150 mM NaCl, 3 mM octyl glucoside. The polarization of the fluorescein label was measured by excitation at 485 nm and emission at 530 nm. Polarization was expressed as a percent of a no compound control, using no MDM2 with F1 9mer as background.